732-341-9500, 9 MULE RD

Advanced Memory Research Institute of New Jersey


Advanced Memory Research Institute offers free, comprehensive memory consultations with our caring staff and physicians to help address you and your loved ones’ questions about memory loss. During your memory consultation, you will discuss your concerns about memory loss, review your medical history, and complete memory evaluations with our team.

We provide individualized education about treatment and care for you and your family, community resources, and answers to your questions. Whether you are already being treated for memory loss or just beginning to have concerns, a free consultation is a great step to take for your memory.

Call us Today to schedule an appointment!


AstraZeneca AZ D5010C00009

A 24-month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s disease (The AMARANTH Study)

RAmP F-AV-45-A25

Registry of Amyloid Positive Patients for Alzheimer’s disease drug Research Trials (RAmP)

Biogen 221AD103

A Randomized, Double-Blind, Placebo-controlled Multi Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in subjects With Prodromal or Mild Alzheimer’s Disease.

Biogen 221AD301

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's disease.


A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate the Efficacy and Safety of BAC in Patient with Alzheimer’s disease or Vascular Dementia.

Eisai BAN2401-G000-201

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease.

Eisai E2006-G000-202

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer’s Disease Dementia.

Eisai E2609-G000-302

A Placebo-Controlled, Double–Blind, Parallel Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.


Effect of LY3202626 on Alzheimer’s disease Progression as Measured by Cerebral 1451 Tau-PET in Mild Alzheimer’s disease Dementia.


A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s disease Dementia (The DAYBREAK Study).


A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s disease Dementia (Extension of Study AZES, The AMARANTH Study).


Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study. A coverage with Evidence Development Longitudinal Cohort Study.

Roche BN29552

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease.

Suven CTP2S1502HT6

A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 23-Week, Placebo-Controlled Study of 50mg and 100mg of SUVN-502 in subjects with moderate Alzheimer’s Disease Currently treated with Donepezil hydrochloride and Mementin hydrochloride.

Meet the Staff

Dr. Sanjiv Sharma is assisted by a skillful team that has over twenty years of clinical research experience and is always ready and willing to answer any questions or concerns that you may have.

Follow us on Facebook